Spineway (ALSPW) - Net Assets
Based on the latest financial reports, Spineway (ALSPW) has net assets worth €23.86 Million EUR (≈ $27.90 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€30.20 Million ≈ $35.31 Million USD) and total liabilities (€6.34 Million ≈ $7.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALSPW financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €23.86 Million |
| % of Total Assets | 79.0% |
| Annual Growth Rate | 30.44% |
| 5-Year Change | 141.99% |
| 10-Year Change | 702.43% |
| Growth Volatility | 164.75 |
Spineway - Net Assets Trend (2009–2024)
This chart illustrates how Spineway's net assets have evolved over time, based on quarterly financial data. Also explore ALSPW current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Spineway (2009–2024)
The table below shows the annual net assets of Spineway from 2009 to 2024. For live valuation and market cap data, see Spineway market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €24.24 Million ≈ $28.34 Million |
+27.23% |
| 2023-12-31 | €19.05 Million ≈ $22.28 Million |
-13.42% |
| 2022-12-31 | €22.01 Million ≈ $25.73 Million |
+5.41% |
| 2021-12-31 | €20.88 Million ≈ $24.41 Million |
+108.41% |
| 2020-12-31 | €10.02 Million ≈ $11.71 Million |
+54.29% |
| 2019-12-31 | €6.49 Million ≈ $7.59 Million |
+587.09% |
| 2018-12-31 | €945.00K ≈ $1.10 Million |
-46.70% |
| 2017-12-31 | €1.77 Million ≈ $2.07 Million |
+36.38% |
| 2016-12-31 | €1.30 Million ≈ $1.52 Million |
-56.97% |
| 2015-12-31 | €3.02 Million ≈ $3.53 Million |
-34.66% |
| 2014-12-31 | €4.62 Million ≈ $5.41 Million |
-9.76% |
| 2013-12-31 | €5.12 Million ≈ $5.99 Million |
+339.87% |
| 2012-12-31 | €1.16 Million ≈ $1.36 Million |
+37.86% |
| 2011-12-31 | €844.99K ≈ $987.88K |
+66.99% |
| 2010-12-31 | €506.00K ≈ $591.57K |
+12.44% |
| 2009-12-31 | €450.00K ≈ $526.10K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Spineway's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12567.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €58.00K | 0.24% |
| Other Components | €28.05 Million | 115.70% |
| Total Equity | €24.24 Million | 100.00% |
Spineway Competitors by Market Cap
The table below lists competitors of Spineway ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dom Maklerski IDM SA
WAR:IDM
|
$6.23 Million |
|
HeartCore Enterprises Inc
NASDAQ:HTCR
|
$6.23 Million |
|
N1 Holdings Ltd
AU:N1H
|
$6.23 Million |
|
Sanginita Chemicals Limited
NSE:SANGINITA
|
$6.23 Million |
|
Spacetalk Ltd
AU:SPA
|
$6.22 Million |
|
Aquila SA
PA:ALAQU
|
$6.22 Million |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
$6.22 Million |
|
Da Lue International Holding Co Ltd
TWO:4804
|
$6.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spineway's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,054,000 to 24,243,000, a change of 5,189,000 (27.2%).
- Net loss of 3,859,000 reduced equity.
- Other comprehensive income increased equity by 1,765,000.
- Other factors increased equity by 7,283,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.86 Million | -15.92% |
| Other Comprehensive Income | €1.76 Million | +7.28% |
| Other Changes | €7.28 Million | +30.04% |
| Total Change | €- | 27.23% |
Book Value vs Market Value Analysis
This analysis compares Spineway's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.72x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €10059.39 | €0.15 | x |
| 2012-12-31 | €13867.52 | €0.15 | x |
| 2013-12-31 | €60999.54 | €0.15 | x |
| 2014-12-31 | €52541.49 | €0.15 | x |
| 2015-12-31 | €34331.59 | €0.15 | x |
| 2016-12-31 | €26000000.00 | €0.15 | x |
| 2017-12-31 | €35460000.00 | €0.15 | x |
| 2018-12-31 | €11812500.00 | €0.15 | x |
| 2019-12-31 | €11594642.86 | €0.15 | x |
| 2020-12-31 | €270756.76 | €0.15 | x |
| 2021-12-31 | €125777.11 | €0.15 | x |
| 2022-12-31 | €38.42 | €0.15 | x |
| 2023-12-31 | €2390.42 | €0.15 | x |
| 2024-12-31 | €0.09 | €0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spineway utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -32.29%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.25x
- Recent ROE (-15.92%) is above the historical average (-70.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 28.24% | 6.63% | 0.96x | 4.43x | €154.11K |
| 2012 | 35.19% | 8.68% | 0.96x | 4.21x | €293.40K |
| 2013 | -1.00% | -0.77% | 0.71x | 1.82x | €-563.81K |
| 2014 | -36.05% | -31.92% | 0.46x | 2.43x | €-2.13 Million |
| 2015 | -55.79% | -29.59% | 0.64x | 2.97x | €-1.99 Million |
| 2016 | -206.92% | -52.81% | 0.54x | 7.27x | €-2.82 Million |
| 2017 | -54.43% | -10.07% | 0.97x | 5.59x | €-1.14 Million |
| 2018 | -436.40% | -59.67% | 0.93x | 7.86x | €-4.22 Million |
| 2019 | -44.29% | -51.49% | 0.44x | 1.97x | €-3.53 Million |
| 2020 | -140.24% | -415.77% | 0.23x | 1.47x | €-15.05 Million |
| 2021 | -7.58% | -36.90% | 0.17x | 1.22x | €-3.67 Million |
| 2022 | -14.26% | -42.21% | 0.27x | 1.26x | €-5.34 Million |
| 2023 | -34.17% | -61.89% | 0.40x | 1.38x | €-8.42 Million |
| 2024 | -15.92% | -32.29% | 0.39x | 1.25x | €-6.28 Million |
Industry Comparison
This section compares Spineway's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,591,767,605
- Average return on equity (ROE) among peers: -8.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spineway (ALSPW) | €23.86 Million | 28.24% | 0.27x | $6.22 Million |
| Crossject (ALCJ) | $-5.48 Million | 0.00% | 0.00x | $110.24 Million |
| I.Ceram SA (ALICR) | $1.24 Million | -26.37% | 1.75x | $155.73K |
| Safe Orthopaedics SA (ALSAF) | $-1.28 Million | 0.00% | 0.00x | $135.92K |
| Amplitude Surgical SAS (AMPLI) | $118.76 Million | -14.86% | 1.08x | $299.85 Million |
| Sartorius Stedim Biotech SA (DIM) | $879.45 Million | 18.32% | 0.60x | $17.02 Billion |
| EssilorLuxottica S. A. (EL) | $38.15 Billion | 5.64% | 0.59x | $92.84 Billion |
| Bonyf NV (MLBON) | $2.68 Million | -38.97% | 0.15x | $2.90 Million |
About Spineway
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The comp… Read more